Neutropenia in adults – significant diagnostic issue
References
- 1. Gibson Ch, Berliner N. How we evaluate and treat neutropenia in adults. Blood. 2014; 124 (8):1251-1258.
- 2. Newburger P, Dale D. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013; 50 (3): 198-206.10.1053/j.seminhematol.2013.06.010
- 3. Gołąb J., Jakóbisiak M. Rozpoznanie drobnoustrojów przez nieswoiste mechanizmy odporności. [w:] Gołąb J, Jakóbsiak M, Lasek W i wsp., red. Immunologia. Nowe wydanie. Warszawa: PWN; 2014, s.234-235.
- 4. Kabata J, Hellman A. Choroby układu krwiotwórczego. Badania laboratoryjne i morfologiczne, [w:] Gajewski P, Interna Szczeklik. Podręcznik chorób wewnętrznych 2014. Medycyna Praktyczna. Kraków; 2014, s. 1578-1579.
- 5. Boxer L. How to approach neutropenia. ASH Education Book. 2012; (1): 174-182.
- 6. Palmblad J, Nilson Ch, Hoglund P, et al. How we diagnose and treat neutropenia in adults. Expert Rev. Hematol. 2016; 9 (5):479-487.
- 7. http://www.genecards.org/cgi-bin/carddisp.pl?gene=ACKR1, dostęp: 10.08.2017.
- 8. Vandenberghe P, Beel K. Severe congenital neutropenia, a genetically heterogenous disease group with an increased risk of AML/MDS. Pediatr Rep. 2011; 3 (2):e9.
- 9. Rosenberg P, Alter B, Bolyard A. Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107 (12):4628-4635.
- 10. Mansoor M, Khan M. A case of Cycylic Neutropenia in adults. J Pak Med Assoc. 2012; 62 (3):289-290.
- 11. Huber M, Andersohn F, Bonder E, et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur J Clin Pharmacol. 2014; 70 (3):339-345.10.1007/s00228-013-1618-1
- 12. Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan. Eur J Clin Pharmacol. 2014;70 (3):339-345.
- 13. Zhong X, Lim EA, Hershman DL, et al. Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events. J Oncol Pract. 2016;12 (3): 245-246.
- 14. Potemski P. Neutropenia, [w:] Krzakowski M, Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013. Gdańsk: Via Medica; 2013, s. 537-547
- 15. Kos-Zakrzewska K, Konopka L. Białaczka limfocytowa z dużych ziarnistych limfocytów T. Onkologia Polska. 2009; 12 (2):65-69.
- 16. Robak T. Rzadsze przewlekłe białaczki limfoidalne. Acta Haematologica Polonica. 2011; 42 (3): 343–355.
- 17. Lustberg M. Management of Neutropenia in Cancer Patients. Clin Adv Hematol Oncol. 2012; 12(10): 825–826.
- 18. Hus M. Leczenie wspomagające w chorobach hematologicznych. [w:] Dmoszyńska A, Robak T, Hus I. Podstawy hematologii. Lublin: Czelej; 2015, s.414-422.
- 19. Ebru R, Yalcinkaya-Erdemci Z, Burcak Cehreli S. Oral findings and clinical implications of patients with congenital neutropenia: a literature review. Turk J. Pediatr. 2013; 55 (3): 241-245.
- 20. Rosenberg P, Zeidler C, Bolyard A, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010; 150 (2):196–199.
- 21. Rosenberg P, Alter B, Bolyard A, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107 (12): 4628–4635.
- 22. Coughlan M, Healy C. Nursing care, education and support for patients with neutropenia. Nursing standard. 2008; 46 (22): 35-41.
DOI: https://doi.org/10.2478/pielxxiw-2018-0006 | Journal eISSN: 2450-646X | Journal ISSN: 1730-1912
Language: English
Page range: 37 - 43
Submitted on: Sep 7, 2017
Accepted on: Jan 25, 2018
Published online: May 19, 2018
Published in print: Mar 1, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Related subjects:
© 2018 Paulina Stefaniuk, Agnieszka Szymczyk, Monika Podhorecka, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.